NR2E3 and cancer: The ability of cancer cells to switch from pyrimidine de novo synthesis via RNR to pyrimidine salvage, to maintain efficient DNA synthesis, and to escape allosteric RNR inhibition with dT resulted in the development of a strategy to co-target RNR and the pyrimidine salvage enzyme dCK.